NCT01711866View on ClinicalTrials.gov

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
DRUG

Rotigotine

Rotigotine up to 16 mg / 24 hours, 4 weeks.

Trial Locations (21)

Unknown

505, Anniston

506, Atlantis

508, Miami Springs

502, Atlanta

501, Dayton

509, Oklahoma City

202, Sarawak

401, Singapore

403, Singapore

101, Busan

102, Busan

108, Daegu

109, Daegu

105, Gyeonggi-do

103, Seoul

104, Seoul

106, Seoul

107, Seoul

301, Linkou District

304, Taichung

305, Taipei

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

UCB BIOSCIENCES GmbH

INDUSTRY